As per attachment

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 13th August 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sirs, Sub: Postal Ballot Notice -Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find enclosed herewith a copy of Postal Ballot Notice pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which is being sent to the Members of the Company seeking their approval for appointment of Ms. Karine J F Natland (DIN:11870917) as a Non-Executive Director & Re-appointment of Mr. Bhushan Akshikar (DIN: 09112346) as Managing Director. In compliance with the Circulars of the Ministry of Corporate Affairs, the said Notice is being sent electronically only to those Members, whose names appear in the Register of Members/ List of Beneficial Owners as received from National Securities Depository Limited (‘NSDL’)/ Central Depository Services (India) Limited (‘CDSL’) and who have registered their e-mail addresses in respect of electronic holdings with NSDL/CDSL through the concerned Depository Participants and in respect of physical holdings with the Company’s Registrar and Share Transfer Agent (RTA) i.e. KFin Technologies Limited (“KFintech”) as on Friday,7th August 2026 (cut-off date). The e-voting shall commence on Friday,14th August 2026 and ends at 5.00 p.m. (IST) on Sunday,13th September, 2026 (both days inclusive). The copy of the said Notice is also available on the website of the Company at https://india-pharma.gsk.com/en-in/investors/shareholder-information/postal-ballot/ and on the website of Kfintech https://evoting.kfintech.com/. This is for your information and record. Thanking you, Yours faithfully, For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President - Administration, Real Estate & Company Secretary CIN: L24239MH1924PLC001151 GlaxoSmithKline Pharmaceuticals Limited Corporate Identity Number (CIN): L24239MH1924PLC001151 Regd. Office: GSK House, Dr. Annie Besant Road, Worli, Mumbai 400 030. Telephone: 022-24959595: Email: in.investorquery@gsk.com Website: https://india-pharma.gsk.com/en-in/ NOTICE OF POSTAL BALLOT Dear Shareholder(s), NOTICE is hereby given pursuant to Sections 108 and 110 of the Companies Act, 2013 (“Act”) and other applicable provisions, if any, of the Act and Rule 22 of the Companies (Management and Administration) Rules, 2014 (“Rules”), as amended from time to time, read with Circular No. 14/2020 dated April 8, 2020, Circular No. 17/2020 dated April 13, 2020, and subsequent circulars issued by the Ministry of Corporate Affairs (“MCA”) the latest being September 22, 2025 (hereinafter collectively referred to as “MCA Circulars”), that the Resolutions appended below are proposed to be passed as Ordinary Resolutions by the Shareholders of GlaxoSmithKline Pharmaceuticals Limited (“Company”) through Postal Ballot only by voting through electronic means (“remote e-voting”). In compliance with the aforesaid MCA Circulars, this Postal Ballot Notice is being sent only through electronic mode to those Shareholders whose e-mail addresses are registered with the Company/Depositories. If your e-mail address is not registered with the Company/Depository, please follow the process provided in the Notes to receive this Postal Ballot Notice, login ID and password for remote e-voting. The communication of the assent or dissent of the Shareholders would only take place through the remote e-voting system. An explanatory statement pursuant to Section 102 and 110 of the Act and other applicable provisions of the Act, pertaining to the said resolution setting out the material facts and reasons thereof, is appended to this Notice. In compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI Listing Regulations”) and pursuant to the provisions of Section 108 and 110 of the Act read with the Rules, the MCA Circulars and Secretarial Standards-2, the Company is providing remote e-voting facility to its Members, to enable them to cast their votes electronically instead of submitting the Postal Ballot Form physically. The Company has engaged the services of KFin Technologies Limited (“KFintech”) for the purpose of providing remote e-voting facility to its members. The instructions for remote e-voting are appended to this Notice. The Notice is also available on the website of the Company at: https://india-pharma.gsk.com/ Pursuant to Rule 22(5) of the Rules, the Board of Directors(“The Board”) of the Company through Resolution passed on 3rd August 2026 has appointed P.N. Parikh (FCS 327 and CP 1228) and failing him Jigyasa Ved (FCS 6488 and CP 6018), of Parikh & Associates, Practicing Company Secretaries, as the Scrutinizer to conduct the Postal Ballot through remote e-voting process in a fair and transparent manner. The remote e-voting period commences from 9.00 a.m. (IST) on Friday,14th August 2026 and ends at 5.00 p.m. (IST) on Sunday,13th September, 2026.The Scrutinizer shall, immediately after the conclusion of voting through remote e-voting, unblock the votes cast through remote e-voting and make, within the prescribed timelines of conclusion of the remote e-voting, a scrutinizer’s report of the total votes cast in favour and against, if any, and submit his report to the Chairperson of the Company, or any person authorized by her. The results of the Postal Ballot will be announced on or before Tuesday,15th September 2026. The said results along with the Scrutinizer’s Report would be intimated to BSE Limited and National Stock Exchange of India Limited, where the equity shares of the Company are listed. Additionally, the results will also be uploaded on the Company’s website https://india-pharma.gsk.com/en-in/investors/shareholder-information and on the website of KFintech https://evoting.kfintech.com/. The results will also be displayed on the Notice Board of the Company at its Registered Office. SPECIAL BUSINESS Resolution 1 Appointment of Ms. Karine J F Natland (DIN:11870917) as a Non-Executive Director To consider and, if thought fit, to pass, the following resolution as an Ordinary Resolution: “Resolved That Ms. Karine J F Natland (DIN: 11870917), who was appointed as an Additional Director of the company by the Board of Directors with effect from 4th August 2026 in terms of Section 161 of the Act, and who is eligible for appointment and has consented to act as a Director of the company and in respect of whom the company has received a notice in writing from a Member under Section 160 of the Act proposing her candidature for the office of Director of the company, be and is hereby appointed as a Non-Executive Director of the company and her office would be liable to retire by rotation. Resolution 2 Re-appointment of Mr. Bhushan Akshikar (DIN: 09112346) as Managing Director To consider and, if thought fit, to pass, the following resolution as an Ordinary Resolution: “Resolved that pursuant to the provisions of Sections 196, 197, 203 and other applicable provisions, if any, of the Act and the rules framed thereunder read with Schedule V of the Act including any statutory modifications or re-enactments thereof for the time being in force, and subject to the approval of any authorities if any, as may required and all other statutory provisions if any, the approval of the Company be and is hereby granted to the re-appointment of Mr. Bhushan Akshikar (DIN: 09112346) as the Managing Director of the Company and payment of remuneration to him for a period of two years from 1st December 2026 to 30th November 2028, on the terms, conditions and stipulat [Showing first 8,000 characters — download PDF for full document]